Skip to main content
Clinical Trials/NCT02400502
NCT02400502
Completed
Not Applicable

Targeting Stress Reactivity in Schizophrenia: Integrating Coping Awareness Therapy (I-CAT) Pilot Trial

University of North Carolina, Chapel Hill1 site in 1 country6 target enrollmentMarch 2015
ConditionsSchizophrenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
University of North Carolina, Chapel Hill
Enrollment
6
Locations
1
Primary Endpoint
Change from Baseline Salivary Cortisol at Six Months
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Integrated Coping and Awareness Therapy is a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. immune indices of stress reactivity, symptom severity) and distal measures (e.g. relapse, quality of life).

Detailed Description

Schizophrenia is one of the most devastating disorders that often results in a lack of functional recovery. Current treatments focused on remediating symptoms have shown only small successes in a return to functioning despite evidence of a dysregulated stress response. There is a fundamental gap in understanding the impact of allostatic overload in persons with schizophrenia that the investigators theorize is associated with deficits in functioning and with an increased vulnerability and relapse risk. The long-term goal is to test an intervention aimed at improving stress reactivity. The objective in this application is to develop and test the feasibility of a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping. The central hypothesis is that an intervention that improves stress reactivity as measured proximally by endocrine, immune, and autonomic indices will result in improved adaptive capacity, better role functioning, reduced risk of relapse, and decreased likelihood of disability for people in the early stages of schizophrenia. The rationale for the proposed research is that stress reactivity may be a modifiable risk factor underlying functional deficits in schizophrenia. The intervention integrates two treatment approaches. The first is based on research showing that mindfulness meditation practice is associated with alterations in the neural processing of stressful events and targets adaptive responses to stress. The second focuses on providing a buffer against stress by using the self-generation of adaptive emotions with a positive psychology intervention, which is potentially associated with building protective social resources. These complimentary interventions provide a comprehensive synergistic approach for this population that could lead to more adaptive coping responses and create a buffer against stress.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
April 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Current or past diagnosis of a schizophrenia spectrum disorder.
  • Has been receiving treatment for psychosis or taking medication for psychosis for less than 5 years.

Exclusion Criteria

  • Has been hospitalized in the last 3 months.
  • Currently practicing meditation
  • Current dependence on alcohol or drugs.
  • History of significant neurological disorder.
  • History of serious head injury (i.e., loss of consciousness longer than 15 minutes, no neuropsychological sequelae, no cognitive rehabilitation treatment post head injury).
  • Illiteracy.
  • Sensory limitation including visual (e.g., blindness, glaucoma, vision uncorrectable to 20/40) or hearing (e.g. hearing loss) impairments.

Outcomes

Primary Outcomes

Change from Baseline Salivary Cortisol at Six Months

Time Frame: Baseline, 6 Months

Salivary cortisol measured before, during and after a social stressor test.

Secondary Outcomes

  • Change from Baseline Urinary Oxidative Stress Level [Isoprostane] at Six Months(Baseline, 6 Months)
  • Change from Baseline Positive and Negative Syndrome Scale (PANSS) Total Score at Six Months(Baseline, 6 Months)
  • Change from Baseline Quality of Life Scale (QLS; Bilker et al., 2003) Total Score at Six Months(Baseline, 6 Months)
  • Change from Baseline Heart Rate Variability (HRV) Measurement at Six Months(Baseline, 6 Months)
  • Change from Baseline Modified Differential Emotions Scale (mDES) Positive Emotion Sub Scale Score at Six Months(Baseline, 6 Months)
  • Change from Baseline Perceived Stress Scale (PSS) Total Score at Six Months(Baseline, 6 Months)
  • Change from Baseline Brief COPE Scale (Assisted Format) Total Score at Six Months(Baseline, 6 Months)
  • Change from Baseline Five Facet Mindfulness Questionnaire (FFMQ) Total Score at Six Months(Baseline, 6 Months)
  • Change from Baseline Psychological Well-Being (PWB) Scale Total Score at Six Months(Baseline, 6 Months)

Study Sites (1)

Loading locations...

Similar Trials